Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease

verfasst von

Philipp Hessmann, Richard Dodel, Erika Baum, Matthias J. Müller, Greta Paschke, Bernhard Kis, Jan Zeidler, Mike Klora, Jens Peter Reese, Monika Balzer-Geldsetzer

Abstract

Introduction Benzodiazepines and related drugs (BZDR) should be avoided in patients with cognitive impairment. We evaluated the relationship between a BZDR treatment and the health status of patients with Alzheimer's disease (AD). Methods Cross-sectional study in 395 AD patients using bivariate and multiple logistic analyses to assess correlations between the prescription of BZDR and patients' characteristics (cognitive and functional capacity, health-related quality of life (HrQoL), neuropsychiatric symptoms). Results BZDR were used in 12.4% (n=49) of all participants. In bivariate analyses, the prescription was associated with a lower HrQoL, a higher need of care, and the presence of anxiety. Multivariate models revealed a higher risk of BZDR treatment in patients with depression (OR 3.85, 95% CI: 1.45 - 10.27). Community-dwelling participants and those treated by neurologists/psychiatrists had a lower risk of receiving BZDR (OR 0.33, 95% CI: 0.12 - 0.89 and OR 0.16, 95% CI: 0.07 - 0.36). Discussion The inappropriate use of BZDR conflicts with national and international guidelines. We suggest evaluating indications and treatment duration and improving the knowledge of alternative therapies in healthcare institutions.

Organisationseinheit(en)

Center for Health Economics Research Hannover (CHERH)

Externe Organisation(en)

Georg-August-Universität Göttingen
Philipps-Universität Marburg
Justus-Liebig-Universität Gießen
Praxis Alexander Etz
Oberberg Fachkliniken
Geriatrie-Zentrum Haus Berge

Typ

Artikel

Journal

Pharmacopsychiatry

Band

52

Seiten

84-91

Anzahl der Seiten

8

ISSN

0176-3679

Publikationsdatum

2019

Publikationsstatus

Veröffentlicht

Peer-reviewed

Ja

ASJC Scopus Sachgebiete

Psychiatrie und psychische Gesundheit, Pharmakologie (medizinische)

Ziele für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Elektronische Version(en)

https://doi.org/10.1055/s-0044-100523 (Zugang: Offen)